Cargando…

New risk score for predicting progression of membranous nephropathy

BACKGROUND: Patients with Idiopathic membranous nephropathy (IMN) have various outcomes. The aim of this study is to construct a tool for clinicians to precisely predict outcome of IMN. METHODS: IMN patients diagnosed by renal biopsy from Shanghai Ruijin Hospital from 2009.01 to 2013.12 were enrolle...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiaofan, Hu, Jing, Xu, Chenni, Gao, Yifan, Wu, Xialian, Yu, Li, Lin, Hong, Ren, Wen, Zhang, Weiming, Wang, Xiaoxia, Pan, Jingyuan, Xie, Nan, Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368730/
https://www.ncbi.nlm.nih.gov/pubmed/30736804
http://dx.doi.org/10.1186/s12967-019-1792-8
_version_ 1783394047575982080
author Xiaofan, Hu
Jing, Xu
Chenni, Gao
Yifan, Wu
Xialian, Yu
Li, Lin
Hong, Ren
Wen, Zhang
Weiming, Wang
Xiaoxia, Pan
Jingyuan, Xie
Nan, Chen
author_facet Xiaofan, Hu
Jing, Xu
Chenni, Gao
Yifan, Wu
Xialian, Yu
Li, Lin
Hong, Ren
Wen, Zhang
Weiming, Wang
Xiaoxia, Pan
Jingyuan, Xie
Nan, Chen
author_sort Xiaofan, Hu
collection PubMed
description BACKGROUND: Patients with Idiopathic membranous nephropathy (IMN) have various outcomes. The aim of this study is to construct a tool for clinicians to precisely predict outcome of IMN. METHODS: IMN patients diagnosed by renal biopsy from Shanghai Ruijin Hospital from 2009.01 to 2013.12 were enrolled in this study. Primary outcome was defined as a combination of renal function progression [defined as a reduction of estimated glomerular filtration rate (eGFR) equal to or over 30% comparing to baseline], ESRD or death. Risk models were established by Cox proportional hazard regression analysis and validated by bootstrap resampling analysis. ROC curve was applied to test the performance of risk score. RESULTS: Totally 439 patients were recruited in this study. The median follow-up time was 38.73 ± 19.35 months. The enrolled patients were 56 (15–83) years old with a male predominance (sex ratio: male vs female, 1:0.91). The median baseline serum albumin, eGFR-EPI and proteinuria were 23(8–43) g/l, 100.31(12.81–155.98) ml/min/1.73 m(2) and 3.98(1.50–22.98) g/24 h, respectively. In total, there were 36 primary outcomes occurred. By Cox regression analysis, the best risk model included age [HR: 1.04(1.003–1.08), 95% CI from bootstrapping: 1.01–1.08), eGFR [HR: 0.97 (0.96–0.99), 95% CI from bootstrapping: 0.96–0.99) and proteinuria [HR: 1.09 (1.01–1.18), 95% CI from bootstrapping: 1.02–1.16). One unit increasing of the risk score based on the best model was associated with 2.57 (1.97–3.36) fold increased risk of combined outcome. The discrimination of this risk score was excellent in predicting combined outcome [C statistics: 0.83, 95% CI 0.76–0.90]. CONCLUSIONS: Our study indicated that older IMN patients with lower eGFR and heavier proteinuria at the time of renal biopsy were at a higher risk for adverse outcomes. A risk score based on these three variables provides clinicians with an effective tool for risk stratification. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12967-019-1792-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6368730
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63687302019-02-15 New risk score for predicting progression of membranous nephropathy Xiaofan, Hu Jing, Xu Chenni, Gao Yifan, Wu Xialian, Yu Li, Lin Hong, Ren Wen, Zhang Weiming, Wang Xiaoxia, Pan Jingyuan, Xie Nan, Chen J Transl Med Research BACKGROUND: Patients with Idiopathic membranous nephropathy (IMN) have various outcomes. The aim of this study is to construct a tool for clinicians to precisely predict outcome of IMN. METHODS: IMN patients diagnosed by renal biopsy from Shanghai Ruijin Hospital from 2009.01 to 2013.12 were enrolled in this study. Primary outcome was defined as a combination of renal function progression [defined as a reduction of estimated glomerular filtration rate (eGFR) equal to or over 30% comparing to baseline], ESRD or death. Risk models were established by Cox proportional hazard regression analysis and validated by bootstrap resampling analysis. ROC curve was applied to test the performance of risk score. RESULTS: Totally 439 patients were recruited in this study. The median follow-up time was 38.73 ± 19.35 months. The enrolled patients were 56 (15–83) years old with a male predominance (sex ratio: male vs female, 1:0.91). The median baseline serum albumin, eGFR-EPI and proteinuria were 23(8–43) g/l, 100.31(12.81–155.98) ml/min/1.73 m(2) and 3.98(1.50–22.98) g/24 h, respectively. In total, there were 36 primary outcomes occurred. By Cox regression analysis, the best risk model included age [HR: 1.04(1.003–1.08), 95% CI from bootstrapping: 1.01–1.08), eGFR [HR: 0.97 (0.96–0.99), 95% CI from bootstrapping: 0.96–0.99) and proteinuria [HR: 1.09 (1.01–1.18), 95% CI from bootstrapping: 1.02–1.16). One unit increasing of the risk score based on the best model was associated with 2.57 (1.97–3.36) fold increased risk of combined outcome. The discrimination of this risk score was excellent in predicting combined outcome [C statistics: 0.83, 95% CI 0.76–0.90]. CONCLUSIONS: Our study indicated that older IMN patients with lower eGFR and heavier proteinuria at the time of renal biopsy were at a higher risk for adverse outcomes. A risk score based on these three variables provides clinicians with an effective tool for risk stratification. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12967-019-1792-8) contains supplementary material, which is available to authorized users. BioMed Central 2019-02-08 /pmc/articles/PMC6368730/ /pubmed/30736804 http://dx.doi.org/10.1186/s12967-019-1792-8 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Xiaofan, Hu
Jing, Xu
Chenni, Gao
Yifan, Wu
Xialian, Yu
Li, Lin
Hong, Ren
Wen, Zhang
Weiming, Wang
Xiaoxia, Pan
Jingyuan, Xie
Nan, Chen
New risk score for predicting progression of membranous nephropathy
title New risk score for predicting progression of membranous nephropathy
title_full New risk score for predicting progression of membranous nephropathy
title_fullStr New risk score for predicting progression of membranous nephropathy
title_full_unstemmed New risk score for predicting progression of membranous nephropathy
title_short New risk score for predicting progression of membranous nephropathy
title_sort new risk score for predicting progression of membranous nephropathy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368730/
https://www.ncbi.nlm.nih.gov/pubmed/30736804
http://dx.doi.org/10.1186/s12967-019-1792-8
work_keys_str_mv AT xiaofanhu newriskscoreforpredictingprogressionofmembranousnephropathy
AT jingxu newriskscoreforpredictingprogressionofmembranousnephropathy
AT chennigao newriskscoreforpredictingprogressionofmembranousnephropathy
AT yifanwu newriskscoreforpredictingprogressionofmembranousnephropathy
AT xialianyu newriskscoreforpredictingprogressionofmembranousnephropathy
AT lilin newriskscoreforpredictingprogressionofmembranousnephropathy
AT hongren newriskscoreforpredictingprogressionofmembranousnephropathy
AT wenzhang newriskscoreforpredictingprogressionofmembranousnephropathy
AT weimingwang newriskscoreforpredictingprogressionofmembranousnephropathy
AT xiaoxiapan newriskscoreforpredictingprogressionofmembranousnephropathy
AT jingyuanxie newriskscoreforpredictingprogressionofmembranousnephropathy
AT nanchen newriskscoreforpredictingprogressionofmembranousnephropathy